Lawrence T. Weiss is a seasoned legal executive with over 25 years of experience in corporate law, regulatory compliance, and strategic advisory roles within the healthcare and medical device industries. He began his career at a prominent New York law firm, where he specialized in mergers and acquisitions, intellectual property protection, and FDA regulatory matters. Weiss later transitioned to in-house counsel positions at several Fortune 500 companies, including a stint as General Counsel for a leading pharmaceutical firm, where he navigated complex litigation and international expansion efforts. Holding a Juris Doctor from Harvard Law School and a bachelor's degree in economics from Yale University, Weiss is recognized for his expertise in guiding organizations through high-stakes legal landscapes while fostering ethical business practices. Throughout his illustrious career, Weiss has achieved notable milestones, including successfully leading the defense in multiple high-profile patent infringement cases that preserved millions in company revenue. He played a pivotal role in orchestrating a landmark acquisition that expanded his previous employer's market share in minimally invasive medical technologies, earning him industry accolades such as the Corporate Counsel Award for Excellence in Legal Strategy. Weiss is also an active contributor to legal scholarship, having authored articles on healthcare compliance in journals like the Harvard Business Law Review, and he serves on the board of the American Health Lawyers Association, where he advocates for innovative regulatory frameworks. In his current role as Senior Vice President and Chief Legal Officer at AngioDynamics Inc., Weiss oversees all legal affairs, including corporate governance, risk management, and compliance with global regulations. He advises the executive team on strategic initiatives, such as product development and market expansions, ensuring alignment with legal standards and ethical guidelines. Under his leadership, AngioDynamics has strengthened its intellectual property portfolio and enhanced its litigation strategies, contributing to the company's growth in the vascular access and oncology sectors. Weiss's forward-thinking approach continues to drive the organization's commitment to innovation while mitigating legal risks in a dynamic industry.